| Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase 2 trial |
| Author |
Wang, K; Yu, HM; Xiang, YJ; Cheng, YQ; Ni, QZ; Guo, WX; Shi, J; Feng, S; Zhai, J; Cheng, SQ |
| Journal |
FUTURE ONCOLOGY |
| Pub Year |
2022 |
| Type |
Article |
| Abstract |
The therapeutic effect of transcatheter arterial chemoembolization (TACE) is limited for patients with hepatocellular carcinoma (HCC). Herein, we designed an open-label, single-arm phase II clinical trial to investigate the efficacy and safety of TACE combined with atezolizumab plus bevacizumab for patients with Barcelona Clinic Liver Cancer (BCLC) stage-B HCC. Patients will initially receive TACE. Atezolizumab and bevacizumab will be initiated 2-14 days after the first TACE session. TACE will be repeated on demand. The primary endpoint is the objective response rate. The secondary endpoints include overall survival, disease control rate, progression-free survival, time to progression and safety. The study results will provide evidence for establishing a novel therapeutic regimen for patients with unresectable HCC. |
| Issue |
18 |
| Volume |
18 |
